Nano-X Imaging GM reports option holdings

Nano-X Imaging Ltd. executive Dara James, GM of the Source & Services Division, filed an initial ownership report showing equity-based compensation.

Rhea-AI Filing Summary

Nano-X Imaging Ltd. executive Dara James, GM of the Source & Services Division, filed an initial ownership report showing equity-based compensation. James holds stock options over 100,000 ordinary shares at an exercise price of $49.68 expiring on January 18, 2031, plus options over 25,000 and 10,000 shares at $17.63 expiring in 2032, and 55,000 shares at $11.52 expiring in 2033. The filing also reports 39,474 ordinary shares consisting of restricted share units granted on February 5, 2026, with half vesting after 12 months and the rest after 24 months.

Insider Trade Summary

5 transactions reported

Mixed 5 txns

Insider Dara James

Role GM Source & Services Division

Type	Security	Shares	Price	Value
holding	Stock Option (right to buy ordinary shares)	--	--	--
holding	Stock Option (right to buy ordinary shares)	--	--	--
holding	Stock Option (right to buy ordinary shares)	--	--	--
holding	Stock Option (right to buy ordinary shares)	--	--	--
holding	Ordinary shares	--	--	--

Holdings After Transaction: Stock Option (right to buy ordinary shares) — 190,000 contracts (Direct); Ordinary shares — 39,474 shares (Direct)

Footnotes (5)

1. F1. The ordinary shares reported in this row consist of shares underlying restricted share units that were granted to the Reporting Person on February 5, 2026, of which 50% will vest on the 12-month anniversary of the grant date and the remaining 50% will vest on the 24-month anniversary of the grant date.
2. F2. The options reported in this row were granted to the Reporting Person by the Issuer on January 18, 2021 and are fully vested and exercisable as of the date of this report.
3. F3. The options reported in this row were granted to the Reporting Person by the Issuer on March 28, 2022 and vest and become exercisable in 16 equal quarterly installments of 6.25% each on each three-month anniversary of the grant date, such that all options reported in this row will be exercisable on the four-year anniversary of the grant date (March 28, 2026).
4. F4. The options reported in this row were granted to the Reporting Person by the Issuer on August 11, 2022 and vest and become exercisable in 16 equal quarterly installments of 6.25% each on each three-month anniversary of the grant date, such that all options reported in this row will be exercisable on the four-year anniversary of the grant date (August 11, 2026).
5. F5. The options reported in this row were granted to the Reporting Person by the Issuer on May 23, 2023 and vest and become exercisable in 16 equal quarterly installments of 6.25% each on each three-month anniversary of the grant date, such that all options reported in this row will be exercisable on the four-year anniversary of the grant date (May 23, 2027).

FAQ

What does Nano-X Imaging (NNOX) Form 3 for Dara James report?

The Form 3 reports Dara James’ existing equity holdings in Nano-X Imaging, including stock options and restricted share units. It is an initial ownership statement, not a record of new share purchases or sales, and outlines exercise prices, expirations, and vesting schedules.

How many Nano-X Imaging stock options does Dara James hold on Form 3?

Dara James holds options over 100,000 ordinary shares at $49.68, 25,000 and 10,000 shares at $17.63, and 55,000 shares at $11.52. These options represent rights to buy Nano-X Imaging shares by specified expiration dates if exercised in the future.

What are the expiration dates of Dara James’ Nano-X Imaging options?

The options over 100,000 shares expire on January 18, 2031. Options over 25,000 and 10,000 shares expire in 2032, and options over 55,000 shares expire on May 23, 2033. Each grant maintains its own clearly defined expiration date.

What restricted share units are reported for Dara James at Nano-X Imaging (NNOX)?

The filing reports 39,474 ordinary shares underlying restricted share units granted on February 5, 2026. Half of these units vest on the 12-month anniversary of the grant date, and the remaining half vest on the 24-month anniversary, subject to the award’s terms.

Is Nano-X Imaging’s Form 3 for Dara James a buy or sell transaction?

The Form 3 is not a buy or sell report; it is an initial statement of beneficial ownership. It lists Dara James’ existing Nano-X Imaging options and restricted share units as of the reporting date, without indicating any new market transactions or exercises.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 11:30 AM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Dara James

(Last) (First) (Middle)

C/O NANO-X IMAGING LTD., OFER TECH PARK

94 SHLOMO SHMELTZER ROAD

(Street)

PETACH TIKVA 4970602

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Nano-X Imaging Ltd. [ NNOX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	GM Source & Services Division

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary shares(1)	39,474	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy ordinary shares)	(2)	01/18/2031	Ordinary shares	100,000	$49.68	D
Stock Option (right to buy ordinary shares)	(3)	03/28/2032	Ordinary shares	25,000	$17.63	D
Stock Option (right to buy ordinary shares)	(4)	08/11/2032	Ordinary shares	10,000	$17.63	D
Stock Option (right to buy ordinary shares)	(5)	05/23/2033	Ordinary shares	55,000	$11.52	D

Explanation of Responses:

1. The ordinary shares reported in this row consist of shares underlying restricted share units that were granted to the Reporting Person on February 5, 2026, of which 50% will vest on the 12-month anniversary of the grant date and the remaining 50% will vest on the 24-month anniversary of the grant date.

2. The options reported in this row were granted to the Reporting Person by the Issuer on January 18, 2021 and are fully vested and exercisable as of the date of this report.

3. The options reported in this row were granted to the Reporting Person by the Issuer on March 28, 2022 and vest and become exercisable in 16 equal quarterly installments of 6.25% each on each three-month anniversary of the grant date, such that all options reported in this row will be exercisable on the four-year anniversary of the grant date (March 28, 2026).

4. The options reported in this row were granted to the Reporting Person by the Issuer on August 11, 2022 and vest and become exercisable in 16 equal quarterly installments of 6.25% each on each three-month anniversary of the grant date, such that all options reported in this row will be exercisable on the four-year anniversary of the grant date (August 11, 2026).

5. The options reported in this row were granted to the Reporting Person by the Issuer on May 23, 2023 and vest and become exercisable in 16 equal quarterly installments of 6.25% each on each three-month anniversary of the grant date, such that all options reported in this row will be exercisable on the four-year anniversary of the grant date (May 23, 2027).

Remarks:

Exhibit 24.1 Power of Attorney

	/s/ Marina Gofman Feler, attorney-in-fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)